Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Grok AI Controversy on X Sparks Global Outrage Over Nonconsensual Images 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
VANCOUVER, British Columbia, March 14, 2017 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, President & CEO, will provide a corporate update at the upcoming Oppenheimer & Co. 27th Annual Healthcare Conference in New York on Wednesday, March 22nd 2017.
Aquinox Presentation Details
Date: Wednesday, March 22nd 2017
Time: 9:45 am Eastern Time / 6:45 am Pacific Time
Location: New York, NY – Westin New York Grand Central
A live audio webcast and archive of the event will be available at:
https://www.veracast.com/webcasts/opco/healthcare2017/05203513909.cfm
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
